Medifast (NYSE:MED) issued an update on its FY 2019
After-Hours earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $5.80-5.90 for the period, compared to the Thomson Reuters consensus estimate of $6.83. The company issued revenue guidance of $$700-710 million, compared to the consensus revenue estimate of $$750.45 million.Medifast also updated its Q4 2019
After-Hours guidance to $1.03-1.13 EPS.
Shares of Medifast stock traded up $5.01 during trading hours on Wednesday, hitting $90.58. The company’s stock had a trading volume of 590,846 shares, compared to its average volume of 310,662. The company has a market capitalization of $1.01 billion, a PE ratio of 19.61 and a beta of 0.65. The business has a fifty day moving average of $94.49 and a 200 day moving average of $110.19. Medifast has a 1-year low of $66.50 and a 1-year high of $159.41.
Medifast (NYSE:MED) last announced its earnings results on Thursday, November 7th. The specialty retailer reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.33 by ($0.01). Medifast had a net margin of 10.70% and a return on equity of 62.93%. The firm had revenue of $190.10 million during the quarter, compared to analysts’ expectations of $194.70 million. During the same quarter last year, the company posted $1.14 earnings per share. Medifast’s revenue for the quarter was up 36.5% compared to the same quarter last year. Analysts anticipate that Medifast will post 5.84 EPS for the current year.
A number of research analysts have commented on the stock. Dougherty & Co downgraded shares of Medifast from a buy rating to a neutral rating in a research note on Friday, November 8th. ValuEngine downgraded shares of Medifast from a hold rating to a sell rating in a research note on Friday, November 8th. Zacks Investment Research downgraded shares of Medifast from a hold rating to a strong sell rating in a research report on Wednesday, November 13th. Finally, DA Davidson downgraded shares of Medifast from a buy rating to a neutral rating and reduced their price target for the stock from $250.00 to $74.00 in a research report on Friday, November 8th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $134.00.
Medifast, Inc, through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands.
See Also: Trading Ex-Dividend Strategy
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.